H. Johansson

发表

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial

M. Fernö, J. Bergh, N. Loman, 2013, Breast Cancer Research and Treatment.

Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.

M. Cazzaniga, B. Bonanni, G. Pelosi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women

M. Cazzaniga, B. Bonanni, S. Gandini, 2001, Breast Cancer Research and Treatment.

Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial.

B. Bonanni, L. Baglietto, C. Robertson, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women.

B. Bonanni, S. Gandini, A. Barreca, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer

B. Bonanni, L. Baglietto, G. Veronesi, 2001, British Journal of Cancer.

Time course of fenretinide‐induced modulation of circulating insulin‐like growth factor (IGF)‐i, IGF‐II and IGFBP‐3 in a bladder cancer chemoprevention trial

A. Barreca, F. Pigatto, C. Robertson, 2000, International journal of cancer.

Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

M. Cazzaniga, B. Bonanni, G. Pelosi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.

B. Bonanni, P. Magni, S. Gandini, 2008, Cancer research.

First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study

G. Mellgren, E. Bifulco, F. Peccatori, 2020, ESMO Open.

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen

B. Bonanni, G. Mellgren, S. Gandini, 2016, Breast Cancer Research and Treatment.

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

A. Luini, M. Cazzaniga, B. Bonanni, 2013, Breast Cancer Research.

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.

M. Cazzaniga, B. Bonanni, G. Pelosi, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect o f B lood T amoxifen C oncentrations o n S urrogate Biomarkers i n a T rial o f D ose R eduction i n H ealthy W omen

B. Bonanni, Alberto Costa, S. Gandini, 1999 .

Vitamin D Receptor Polymorphisms and Cancer.

S. Gandini, S. Raimondi, H. Johansson, 2020, Advances in experimental medicine and biology.

Ethnicity as modifier of risk for Vitamin D receptors polymorphisms: comprehensive meta-analysis of all cancer sites.

S. Gandini, S. Raimondi, S. Caini, 2020, Critical reviews in oncology/hematology.

Association of Molecular Subtypes with Ki-67 Changes in Untreated Breast Cancer Patients Undergoing Pre-surgical Trials Epidemiology and Biostatistics

M. Cazzaniga, B. Bonanni, G. Pruneri, 2022 .

Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort

B. Bonanni, S. Gandini, C. Zanzottera, 2021, Nutrients.

A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients

B. Bonanni, G. Pruneri, S. Gandini, 2016, Cancer Prevention Research.

Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease

B. Bonanni, L. Boni, M. Digennaro, 2021, Clinical Cancer Research.

Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

B. Bonanni, G. Mellgren, L. Boni, 2021, NPJ breast cancer.

Quality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women

B. Bonanni, S. Gandini, D. Serrano, 2018, Cancer Prevention Research.

Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial

B. Bonanni, A. Testori, P. Queirolo, 2021, Nutrients.

Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer

A. Luini, M. Cazzaniga, B. Bonanni, 2006, Breast Cancer Research and Treatment.

A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer

M. Cazzaniga, B. Bonanni, G. Pruneri, 2017, Cancer Prevention Research.

An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors

Dorothy D. Sears, Sheri J. Hartman, A. Hubbard, 2021, Clinical Epigenetics.

BsmI polymorphism of vitamin D receptor gene and cancer risk: a comprehensive meta-analysis.

S. Gandini, D. Serrano, S. Raimondi, 2014, Mutation research.

Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial

B. Bonanni, G. Mellgren, P. Maisonneuve, 2011, The Pharmacogenomics Journal.

Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.

B. Bonanni, U. Veronesi, P. Maisonneuve, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD3-08: Effects of low dose tamoxifen on circulating risk biomarkers in a phase III trial in breast pre-invasive disease

B. Bonanni, L. Boni, M. Digennaro, 2020 .

Life style and interaction with microbiota in prostate cancer patients undergoing radiotherapy: study protocol for a randomized controlled trial

G. Pravettoni, L. Nezi, S. Gandini, 2022, BMC cancer.

RE: Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients.

S. Gandini, S. Raimondi, H. Johansson, 2015, Journal of the National Cancer Institute.

Abstract P4-11-16: Low serum adiponectin level is an independent risk factor of DCIS in postmenopausal women at increased risk of breast cancer

J. Cuzick, B. Bonanni, S. Gandini, 2015 .

Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women.

B. Bonanni, A. Barreca, C. Robertson, 1999, European journal of cancer.

Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk.

Sara Gandini, Patrick Maisonneuve, Sara Raimondi, 2009, Carcinogenesis.

Biologic activity of tamoxifen at low doses in healthy women.

B. Bonanni, P. Boyle, U. Veronesi, 1998, Journal of the National Cancer Institute.

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

A. Luini, M. Cazzaniga, B. Bonanni, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial

T. Fornander, A. Sverrisdottir, H. Johansson, 2009, Breast Cancer Research and Treatment.

Telomere length and the risk of cutaneous melanoma and non-melanoma skin cancer: a review of the literature and meta-analysis.

Vincenzo De Giorgi, Sara Gandini, Sara Raimondi, 2015, Journal of dermatological science.

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.

A. Luini, M. Cazzaniga, G. Pelosi, 2003, Journal of the National Cancer Institute.

Adherence to WCRF/AICR cancer prevention recommendations and metabolic syndrome in breast cancer patients

F. Berrino, P. Pasanisi, G. Gargano, 2016, International Journal of Cancer.

A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer

M. Cazzaniga, B. Bonanni, G. Pruneri, 2015, Cancer Prevention Research.

Development of an HPLC-MS/MS Method for the Determination of Silybin in Human Plasma, Urine and Breast Tissue

B. Bonanni, A. Riva, G. Petrangolini, 2020, Molecules.

Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.

M. Cazzaniga, B. Bonanni, G. Pruneri, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

B. Bonanni, R. Gelber, A. Goldhirsch, 2016, Breast Cancer Research.

A Two-by-Two Factorial Trial Comparing Oral with Transdermal Estrogen Therapy and Fenretinide with Placebo on Breast Cancer Biomarkers

M. Cazzaniga, B. Bonanni, L. Baglietto, 2004, Clinical Cancer Research.

Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non–Muscle-Invasive Bladder Cancer

S. Bruno, E. Garrone, A. Decensi, 2016, Cancer Prevention Research.

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial

U. Hofmann, A. Luini, M. Cazzaniga, 2014, Breast Cancer Research and Treatment.

Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis

B. Bonanni, G. D'aiuto, Alberto Costa, 2007, Breast Cancer Research and Treatment.

Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.

G. Viale, M. Colleoni, L. Zorzino, 2004, Anticancer research.

Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.

A. Luini, A. Goldhirsch, G. Viale, 2009, Anticancer research.

Serum EGFR and serum HER‐2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy

P. Maisonneuve, M. Colleoni, A. Rocca, 2007, Cancer.

The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial

B. Bonanni, S. Gandini, D. Serrano, 2008, Ecancermedicalscience.

Metabolic syndrome and breast cancer prognosis

F. Berrino, B. Bonanni, S. Panico, 2014, Breast Cancer Research and Treatment.

Lapatinib Activity in Premalignant Lesions and HER-2–Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial

A. Luini, B. Bonanni, G. Pruneri, 2011, Cancer Prevention Research.

Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials

Dorothy D. Sears, Sheri J. Hartman, B. Bonanni, 2022, Journal of Translational Medicine.

Effect of tamoxifen at low doses on ultrasensitive C‐reactive protein in healthy women

B. Bonanni, S. Gandini, M. Sandri, 2003, Journal of Thrombosis and Haemostasis.

Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women

M. Cazzaniga, B. Bonanni, S. Pecorelli, 2002, Circulation.

Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer

B. Bonanni, L. Baglietto, D. Serrano, 2004, Breast Cancer Research and Treatment.

Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.

L. Mariani, Alberto Costa, U. Veronesi, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.

L. Mariani, T. Camerini, R. Miceli, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Effect of the Synthetic Retinoid Fenretinide on Circulating Free Prostate-Specific Antigen, Insulin-Like Growth Factor-I, and Insulin-Like Growth Factor Binding Protein-3 Levels in Men with Superficial Bladder Cancer

L. Baglietto, D. Serrano, A. Decensi, 2005, Clinical Cancer Research.

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences

R. Gelber, A. Goldhirsch, A. Coates, 2014, Breast Cancer Research and Treatment.

Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women

Laura Baglietto, Sara Gandini, Enrico Cassano, 2008, Breast Cancer Research and Treatment.

Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.

M. Cazzaniga, B. Bonanni, P. Magni, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia

A. Luini, M. Cazzaniga, B. Bonanni, 2009, Clinical Cancer Research.

Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.

R. Gelber, A. Goldhirsch, J. Bernhard, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide

M. Cazzaniga, B. Bonanni, S. Gandini, 2013, Breast Cancer Research and Treatment.

Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial.

B. Bonanni, P. Brown, J. Lee, 2023, JAMA oncology.

Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer

B. Bonanni, G. Mellgren, S. Gandini, 2019, The Pharmacogenomics Journal.

Vitamin D Supplementation and Adherence to World Cancer Research Fund (WCRF) Diet Recommendations for Colorectal Cancer Prevention: A Nested Prospective Cohort Study of a Phase II Randomized Trial

B. Bonanni, S. Gandini, M. Zampino, 2023, Biomedicines.

A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk

J. Cuzick, B. Bonanni, I. Šestak, 2021, Cancers.

Ki-67 Expression after Tamoxifen Given Preoperatively Predicts Disease Free Survival and Overall Survival in Women with Operable ER-Positive Breast Cancer.

A. Luini, M. Cazzaniga, B. Bonanni, 2009 .

BsmI polymorphism of vitamin D receptor gene and cancer risk: a comprehensive meta-analysis.

S. Gandini, D. Serrano, S. Raimondi, 2014, Mutation research.

Inflammatory and Metabolic Biomarker Assessment in a Randomized Presurgical Trial of Curcumin and Anthocyanin Supplements in Patients with Colorectal Adenomas

B. Bonanni, A. Decensi, H. Johansson, 2023, Nutrients.

Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation

Parijatham S. Thomas, D. Serrano, L. Vornik, 2024, NPJ breast cancer.

The Effect of Diet on Breast Cancer Recurrence: The DIANA-5 Randomized Trial

B. Bonanni, V. Krogh, S. Panico, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.

M. Cazzaniga, B. Bonanni, P. Magni, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study

D. Serrano, H. Johansson, M. Lazzeroni, 2024, Cancers.

A Mediation Analysis of Obesity and Adiponectin Association with Postmenopausal Breast Cancer Risk: A Nested Cohort Study in the International Breast Cancer Intervention Study II (IBIS-II) Prevention Trial

I. Šestak, A. Decensi, H. Johansson, 2024, Nutrients.